June 4, 2025 06:42 AM EDTUpdated 02:30 PM
Deals
R&D

Lil­ly makes a move for long-act­ing in­cretins in tech deal with Swedish biotech

Anna Brown

News Reporter

Eli Lil­ly has tapped Ca­mu­rus in a deal worth up to $870 mil­lion for its drug de­liv­ery tech­nol­o­gy to de­vel­op four long-act­ing in­cretin can­di­dates. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Oma­da Health is go­ing pub­lic on Fri­day at a $1.1B val­u­a­tion

Biotech ranks as Chi­na’s best shot to sur­pass US in emerg­ing tech, re­port finds

A decade af­ter its ill-fat­ed $40.5B megadeal, Te­va piv­ots from gener­ics to in­no­va­tion

FDA's Makary looks at ways to speed drug ap­provals, talks about cut­ting user fees

Trump's health ap­pointees pledge sup­port for cell and gene ther­a­pies at FDA round­table

sponsored

Cy­ti­va and Eu­rek­aBio form strate­gic part­ner­ship to ad­vance lentivi­ral vec­tor man­u­fac­tur­ing for cell and gene ther­a­py ...

A service from the Financial Times